SN-38 is a chemotherapeutic compound with potent antitumor effects. However, its 9 clinical application is currently limited due to its poor solubility and low stability at physiological 10 pH. Liposomes and cyclodextrins have been long studied for the solubilization and delivery of 11 hydrophobic compounds. Aiming to combine the advantages from both systems, we attempted 12 to develop an SN-38-in-cyclodextrin-in-liposome formulation. We found that the encapsulation 13 of SN-38-SBE-β-CD inclusion complexes in the lumen of liposomes was not possible, owing to 14 the disassembly of liposomes and the formation of lipid nanoparticles, as revealed by size 15 exclusion chromatography and single nanoparticle fluorescence microscopy. Interestingly, the 16 retention time of SN-38 inside SN-38-SBE-β-CD-lipid nanoparticles is higher than in liposomes, 17 whereby SN-38 was directly loaded into the lipid film. The toxicity of purified SN-38-SBE-β-CD-18 lipid nanoparticles was assayed in cultured cancer cells, showing no therapeutic advantage 19 compared to bulk SN-38-SBE-β-CD complexes. Further formulation optimization, in particular an 20 increased concentration of the nanoparticles, will be necessary to obtain cytotoxicity effects. 21 Moreover, the results highlight the value of fluorescence imaging of single, surface-immobilized 22 nanoparticles, in the development of liposomal delivery systems such as drug-in-cyclodextrin-23 in-liposomes. 24
INTRODUCTION 1
SN-38, 7-ethyl-10-hydroxycamptothecin, is the active metabolite of Irinotecan (CPT-11), a 2 compound approved by the Food and Drug Administration agency for use in the treatment of 3 recurrent metastatic colorectal cancer. SN-38 interfers with the human topoisomerase I, 4
impeding both DNA replication and transcription [1] [2]. 5
The therapeutic activity of CPT-11 depends on its conversion efficiency to SN-38. Upon 6 administration, only 2 to 8% of CPT-11 is metabolized into the active SN-38 through 7 carboxylesterase mediated cleavage in the liver [3, 4] . The conversion rate is relatively 8 dependent on genetic variability, making it unpredictable, posing significant life-threatening 9 risks and complicating clinical management of patients [3, 5] . Unlike its precursor, SN-38 does 10 not require activation in the liver. Moreover, in vitro toxicity studies indicate that SN-38 is up to 11 1,000-fold more potent than CPT-11 against different tumor cell lines [5] . Additionally, the 12 biological half-life of SN-38 is much longer than that of CPT-11 [3] . Thus, SN-38 holds great 13 pharmaceutical advantage over CPT-11 as an anticancer candidate. 14 Despite its potent activity toward tumor cells in vitro, clinical application of SN-38 remains 15 challenging due to its extremely poor solubility in aqueous solutions and other pharmaceutically 16 acceptable solvents [6] . SN-38 exists in two pH-dependent reversible forms: an active lactone 17 ring at acidic pH and an inactive carboxylate form at basic pH (Fig. 1a ). The closed lactone moiety 18 is a required feature for the anti-tumor activity of SN-38. Unfortunately, at physiological pH, the 19 active lactone is partially converted into the inactive carboxylate that becomes dominant at 20 equilibrium [3] . In addition, in vivo, the carboxylate form tightly binds to human serum albumin 21 with an affinity 150-fold higher than the lactone form, further shifting the lactone-carboxylate 22 equilibrium towards the inactive state [7] . Therefore, the instability of the lactone SN-38 under 23 physiological conditions represents a major challenge towards an effective therapy with 3 In this work, we aimed at developing two types of lipid-based drug delivery systems for SN-38 1 in order to overcome some of the above challenges: SN-38-loaded liposomes and SN-38-in-2 cyclodextrin-in liposomes. Liposomal delivery systems can solubilize hydrophobic drugs in their 3 lipid bilayer [8] , improve their stability [9] and tumor targeting ability in vivo [10] , and reduce 4 their systemic toxicity. Previous efforts have attempted to incorporate camptothecin derivates 5 into liposomes [5] . It has been shown that interaction with a lipid bilayer stabilizes the lactone 6 ring moiety of camptothecin drugs by protecting it from hydrolysis [11] . Furthermore, liposomes 7 prevent the complexation of the carboxylate form with human serum albumin [12] . In 2004, 8 Zhang et al. [3] described the development of a non-targeted SN-38 liposomal formulation (LE-9 SN-38) that improved the pharmacokinetic profile, safety and tolerability of SN-38 in its phase I 10 trial investigation for the treatment of metastatic colorectal cancer [13] . 11
Although liposomalization of drugs can enhance their tumor distribution passively through the 12 enhanced permeability and retention effect [14] [15] [16] , insufficient uptake at tumor sites and 13 nonspecific association to healthy tissues decrease their therapeutic efficacy and may provoke 14 harmful side effects [17] . Active targeted delivery increases tissue selectivity and thus reduces 15 side effects [18] . Folic acid has been extensively investigated as a ligand for tumor-specific and 16 targeted drug delivery because its receptors (folic acid receptors, FR) are overexpressed on the 17 surface of a variety of malignant tumor cells, while being minimally distributed in healthy tissues 18 [19] . Folate-conjugated lipidic nanocarriers have been shown to increase drug accumulation in 19 FR-overexpressing tumors [20] . Different chemotherapeutic agents have been delivered using 20 liposomes conjugated to the folate ligand via a polyethyleneglycol spacer [21] . Recently, a study 21 has shown that SN-38-loaded, folate-functionalized liposomes can target breast cancer tumors 22 and reduce unspecific SN-38 toxicity in vivo [22] . 23
Incorporation of hydrophobic drugs in the lipid bilayer of liposomes is always restricted in terms 24 of the drug-to-lipid mass ratio [23, 24] . Thus, new strategies to further enhance loading 25 mg/ml. Liposomes were downsized by extrusion to obtain SUVs as described above, except that 18 temperature was set to 60 ˚C. 19 20
Dynamic light scattering 21
The size distribution of liposomes was analyzed by dynamic light scattering (DLS). For a typical 22 experiment, 10 µl of the SUV solution was diluted in 90 µl of PBS buffer and placed into a 23 disposable microcuvette (ZEN0040, Malvern). The measurements were carried out on a 24 8 Zetasizer Nano ZS (Malvern, UK) operating at a scattering angle of 173° at room temperature. 1
For each condition, each run consisted of three measurements of 12-20 acquisitions per sample. 2 Liposome colloidal stability was studied over time by monitoring their mean size and size 3 distribution every day for 5 days upon storage at 4 °C. 4 5
Size exclusion chromatography 6
A homemade size exclusion chromatography column was prepared by filling the neck of a 150 7 mm Pasteur glass pipette with cotton. The cotton was washed with MilliQ water and 1.7 ml or 2 8 ml of Sepharose beads 4B (45-165 µm bead diameter) were added. Columns were packed 9 overnight at room temperature. Prior to usage, columns were washed three times with a volume 10 equal to that of the beads added. Column washes were done with either sample buffer or 11 ammonium acetate (25 mM, pH 8.6) depending on the experiment. Liposome samples pre-12 incubated for 0, 48 or 72 h at 4 °C were added when the eluent level reached the top of the gel. 13
Buffer flow was driven by gravity only. The sample was allowed to penetrate the gel entirely 14 prior to adding repetitively small volumes of buffer for continuous elution. A sample volume 15 between 30 and 150 µl was purified in each column, and 30-48 elution samples were collected 16 in microcentrifuge tubes. Two drops of eluate were collected per tube. 17
18

Fluorescence spectroscopy 19
Elution samples of 10 µl were dispensed in wells of a black 384-well microplate (Greiner Bio 20 One). Fluorescence intensity was measured with a CLARIOstar® Microplate reader (BMG 21 LABTECH's) using 379/10 nm excitation and 548/10 nm emission wavelengths for SN-38, and 22 562/15 nm excitation and 606/10 nm emission wavelengths for the liposome membrane dye 23 (Texas Red). A focal height of 11 mm was set for all measurements. Gains of 1000, 1500, 2000, 24 9 or 3000 for SN-38 and Texas Red were used depending on the experiment . The emission spectra  1   of SN-38 and Texas Red were measured on a glass-bottom 384-well microplate (µClear®, non-2 binding, Greiner Bio One) using excitation wavelengths of 379/10 nm and 562/10 nm, 3 respectively, a gain of 3000 and a focal height of 3 mm. 4 5
Preparation of chambered coverslips 6
Chambered coverslips were fabricated to image liposomes. First, two holes with diameters of 5 7 and 7 mm were drilled into a coverslide (76  26 mm, Menzel-Gläser) with a Sand Blaster. After 8 a brief washing step with MilliQ water, coverslides were consecutively sonicated in a bath 9 (Branson 1510 ultrasonic cleaner, Ultrasonics) with 2% Hellmanex and MilliQ water for 10 min 10 and with 100% ethanol. Dried coverslides were plasma cleaned in a Harrick Plasma PDC-002. 11
Coverslips (24  60 mm, Menzel-Gläser) were also cleaned following the protocol described 12 above. A drop of Norland optical adhesive (NOA 81, Ultraviolet curing) was applied to the 13 surroundings of the apertures on a single side of the coverslides, and a clean coverslip was 14 immediately sealed on top by 5 min irradiation with a 365-nm light using a Promed UVL 36 lamp. 15
The chambered coverslips were incubated for 48 h at 55 °C, washed as mentioned above, and 16 stored in clean Petri dishes until usage. 17
18
Fluorescence confocal microscopy 19
The 5-mm wide well of the chambered coverslip was functionalized with 10 µl of 1 mg/ml BSA-20
Biotin (Thermo Fisher Scientific) for 5 min, washed three times with MilliQ water, incubated with 21 10 µl of 1 mg/ml Neutravidin (Thermo Fisher Scientific) for 5 min at room temperature, washed 22 three times with MilliQ water and finally incubated with 10 µl PBS. Before imaging, PBS was 23 replaced with 7-10 µl of the lipid sample (liposomes or nanoparticles). The 7-mm hole was filled 24 10 with 15 µl MilliQ water to avoid sample evaporation during imaging. After sample addition, 1 chambered coverslips were sealed with a 1-mm thick silicone spacer (Press-to-seal silicone 2 sheet, Life technologies) and a clean coverslip. Imaging was performed using a laser scanning 3 confocal microscope (A1+, Nikon) equipped with a 100 oil immersion objective. The 405 nm 4 and 561 nm laser lines with appropriate dichroic mirrors and emission filters were used to image 5 SN-38 and Texas Red, respectively. were injected between sample runs to clean the column and avoid sample-to-sample 20 contaminations. The flow rate was 0.5 ml/min and the maximum pressure in the column was 21 600 bar. Samples were loaded into low-volume HPLC vial inserts (250 µl, Agilent) in 2-ml screw 22 top vials (Agilent) and kept at 4 °C until injection. All samples containing liposomes or lipid 23 nanoparticles were pre-diluted ten times in methanol, vortexed for 30 sec and spun down in a 24 tabletop centrifuge for 30-60 sec to remove any precipitates. HPLC samples containing 90% 25 methanol were injected soon after preparation to avoid conversion of carboxylate SN-38 into 1 lactone SN-38. Sample injection volumes were 1 µl, 2 µl or 10 µl depending on the experiment. β-CD were prepared by serial dilutions in the same buffer. All tubes were vortexed and incubated 5 at 37 °C until all SBE-β-CD was dissolved. Next, SN-38 was added to a final concentration of 100 6 µM in each tube, resulting in samples with the following SN-38 to SBE-β-CD molar ratios: 1:8, 7 1:100, 1:480, 1:1000 and 1:1500. Samples were sonicated for 15 min in a bath sonicator, 8 tumbled overnight at room temperature to form SN-38-SBE-β-CD complexes, centrifuged for 5 9 min at 13,200 rpm, and 900 µl were carefully transferred to new tubes in order to remove 10 undissolved precipitates. Quantitation of SN-38 solubilization was carried out by measuring SN-11 38 fluorescence intensity by HPLC (1-µl sample injection) and by spectrofluorometry using a 12 plate reader, as described above. For each technique, a solubility curve was generated by 13 plotting the measured fluorescence intensity values (plate reader) or the chromatogram peak 14 areas (HPLC) against the molar excess of cyclodextrin used in each condition. 15
We also prepared samples with lower ratios of SN-38 to SBE-β-CD, namely 1.25:1 and 1:8, and 16 varying absolute amounts of both molecules. All samples were sonicated for 15 min and rotated 17 at 20 rpm overnight at room temperature. Aliquots of 600 µl from each sample were filtered 18 with a 0.45-µm filter to remove undissolved SN-38 and 2 µl were injected for HPLC analysis. The SN-38 and membrane dye fluorescence was measured as previously described. Liposomes were prepared in acidic PBS (pH 5.3) to maintain SN-38 in its active state. SN-38-1 doped HSPC-liposomes were immobilized on a glass coverslip and imaged by fluorescence 2 microscopy. The SUVs were localized through their membrane dye. They appear as discrete 3 diffraction-limited spots with a width <1 µm (Fig. 2a) . The population-wide liposome size 4 distribution was determined by light scattering. Both SN-38-loaded SUVs and control SUVs had 5 a similar average diameter of 225 and 216 nm, respectively, 7 days after liposome production 6 ( Fig. 2b, Fig. S1 ). These results indicate that the inclusion of SN-38 does not influence vesicle 7 size, aggregation state or stability. 8
The ability of folate-modified HSPC-liposomes to target living cells was investigated in the 9 absence of SN-38 using cultured KB cells. The specific role of the folate ligand in cellular 10 interaction was evaluated by performing a competitive binding assay in which 5 mM of free folic 11 acid was added to the medium to saturate the cell-surface folate receptors. Fluorescence 12 imaging up to 2 h after incubating liposomes with the cells revealed that SUVs interact with the 13 plasma membrane of KB cells mostly in the absence of free folate (Fig. 2c 
SN-38 is rapidly released from folate-HSPC liposomes 1
The stability of SN-38 in the liposome membrane was investigated by size exclusion 2 chromatography to quantify the amounts of free and liposome-loaded SN-38 molecules. The 3 spectrally separated SN-38 and membrane dye fluorescence signals allowed us to monitor their 4 respective levels in the course of elution. The corresponding intensity profiles are shown in Fig.  5 3a, b. Folate-modified HSPC-liposomes were identified as a single peak spanning across eight 6 fractions, both in the presence and absence of SN-38. SN-38 mostly eluted as one peak after 7 fraction 20, representing the free drug that has been released from the SUVs. Interestingly, a 8 fraction of SN-38 co-eluted with liposomes when the sample was left to pre-incubate for 48 h 9 prior column purification (Fig. 3b ). Although the underlying mechanism requires clarification, we 10 decided to quantify the rate of release under this condition and to determine the amounts of 11 active (lactone) and inactive (carboxylate) SN-38. 12 SN-38 was incubated in buffers with different pH values to populate the solution with a single 13 or the two species. The lactone and carboxylate SN-38 forms can clearly be distinguished as two 14 baseline-separated peaks by HPLC (Fig. 3c ). The peaks eluting at 1.8-2.0 min and 6.2-6. 20 difference was found between the three conditions after 2 h incubation ( Fig. 3e ), suggesting that 1 SN-38 is released from the membrane and undergo conversion in the bulk solution. 2 Alternatively, SN-38 interacting with, or entrapped in liposomes would get inactivated. To 3 discriminate between these two scenarios, the SN-38 release rate from HSPC-liposomes was 4 studied by a two-step column purification (Fig. 3f ). All liposome-containing fractions in the first 5 chromatography were pooled and subjected to a second purification after 20 min (Fig. 3g ). Less 6 than 10% of the SN-38 that had co-eluted with liposomes in the first purification step was 7 recovered (Fig. 3h ). This result shows that SN-38 is rapidly released from the HSPC liposomes 8 into the outside solution, where it can be converted into the carboxylate form under basic 9 conditions. 10 
Complexation of SN-38 with SBE-β-CD increases the drug solubility 18
To avoid premature release of SN-38 from HSPC vesicles, we aimed to create an SN-38-in-19 cyclodextrin-in-liposome system as a novel strategy for liposomal SN-38 delivery (Fig. 4a) . First, 20
we addressed the ability of SBE-β-CD to solubilize SN-38 without affecting its conversion rate. 21
We verified that complexation with SBE-β-CD does not influence the elution profile of the 22 lactone SN-38 by HPLC (Fig. S2 ). An SN-38 solubility curve was plotted by measuring the amount 23 of solubilized drug (100 µM input concentration) as a function of SBE-β-CD concentration (Fig.  24   4b) . The solubility of SN-38 increased linearly with respect to cyclodextrin concentration until a 25 23 molar excess of SBE-β-CD to SN-38 of 1,000 was reached, after which the curved plateaued. A 1 good agreement was found between the plate reader and HPLC methods. Maximum SN-38 2 solubilization is observed at a 1,000-fold molar excess of SBE-β-CD for concentrations of SN-38 3  100 µM. SN-38 solubility increases by more than 70-fold compared to a molar ratio 1:8. 4
Fluorescence-based calibration curves were constructed to enable SN-38 quantification in 5 liposome samples from HPLC and plate reader measurements. As shown in Fig. 4c , the obtained 6 curves were linear across four orders of magnitude of SN-38 concentrations. 7
The solubilization profile of SN-38 was further examined at lower relative amounts of SBE-β-CD, 8 specifically at 1.25:1 and 1:8 SN-38 to SBE-β-CD molar ratios. The absolute concentrations of the 9 drug and of SBE-β-CD were varied, while maintaining the ratio values constant, and the 10 concentration of soluble SN-38 was determined by HPLC after discarding the insoluble fraction. 11
Complexation with 64.9 µM of SBE-β-CD enhances SN-38 solubility by about 1.5 and 10 times at 12 a 1.25:1 and 1:8 molar ratio, respectively (Fig. 4d) . 
Entrapment of SN-38-SBE-β-CD complexes into liposomes leads to the formation of stable SN-7
38-SBE-β-CD-lipid nanoparticles 8
Next, we aimed to encapsulate pre-formed SN-38-SBE-β-CD inclusion complexes inside the 9 lumen of folate-conjugated HSPC-liposomes. Because SBE-β-CD can deplete lipids [36], we 10 anticipated that liposomes may not be stable in the presence of high concentration of either 11 SBE-β-CD or SN-38-SBE-β-CD complexes. We first verified that the conditions to swell the lipid 12 film did not inactivate SN-38 ( Fig. S3 ). Then, liposomes were produced by lipid film hydration 13 with an aqueous solution containing pre-incubated SN-38 (44 µM) and SBE-β-CD at a 1:8 molar 14 ratio. The sample was analysed by size exclusion chromatography. As shown in Fig. 5a , the 15 membrane dye signal was split in two distinct populations, in contrast to the single-peak profile 16 obtained in the absence of SBE-β-CD ( Fig. 3a, b) . The earlier population corresponds to the 17 typical profile of liposomes, while the later may support the presence of smaller lipid 18 nanoparticles resulting from partly solubilized liposomes by cyclodextrin. A similar characteristic 19 elution profile was observed when the lipid film was rehydrated with SBE-β-CD only (Fig. 5b,  20 middle panel). We found that SN-38-SBE-β-CD inclusion complexes co-eluted with the lipid 21 nanoparticle fractions but not with the vesicles. No changes of the co-elution profile were 22 observed when swelling duration was extended from 2 h to overnight (Fig. S4) or when freeze-23 thaw cycles were applied to increase the encapsulation efficiency (Fig. 5c ). Moreover, preparing 24 lipid particles of bigger diameter (extruded across a membrane with 400-nm pores) to better 25 accommodate SBE-β-CD-SN-38 complexes in the lumen of vesicles failed to enhance 1 encapsulation (Fig. 5c ). 2 Based on these results, we hypothesized that the late-eluting particles are composed of water 3 soluble lipid-cyclodextrin-SN-38 complexes as a product of lipid depletion and complexation by 4 SBE-β-CD. We examined the elution profile of SN-38-SBE-β-CD inclusion complexes in the 5 absence of lipids and found that it matches with the one observed in the presence of HSPC 6 liposomes ( Fig. 5b, right panel) . Therefore, it is not possible to unambiguously conclude from 7 these chromatography data that the SN-38-SBE-β-CD and lipid-SBE-β-CD inclusion complexes 8 directly interact or assemble into mixed supramolecular structures. To further study the nature 9 of these molecular complexes, we prepared lipid-SN-38-SBE-β-CD samples and attempted to 10 characterize the purified fractions corresponding to the second population by fluorescence 11 confocal microscopy. Lipid particles were immobilized on the glass surface through their biotin 12 linker and imaged with the Texas Red dye. SN-38 fluorescence was also imaged and its 13 localization analysed. Larger and brighter lipid particles were found to also exhibit SN-38 14 fluorescence, unlike the more abundant smaller and dimer structures (Fig. 5d ). Increasing the 15 concentration of SBE-β-CD from 800 µM to 8 mM (the concentration of SN-38 was also increased 16 10 times to keep the same molar ratio) did not affect the apparent size of the lipid aggregates 17 ( Fig. 5d ). These results of visualization of single particles suggest direct interaction between SN-18 38-SBE-β-CD and lipid-SBE-β-CD inclusion complexes, at least for the bigger structures. The fact 19 that these lipid-SN-38-SBE-β-CD aggregates retained a fraction of SN-38 even 24 h after dilution 20 in physiological buffer (PBS pH 7.4) through size exclusion chromatography prompted us to 21 explore their antitumor effect in vitro. 
SN-38-SBE-β-CD-lipid nanoparticles can interact with cancer cells 6
The first step in the antitumor mechanism of a therapeutic lipid nanoparticle is the interaction 7 with the plasma membrane and subsequent internalization. Thus, we investigated the 8 interaction of SN-38-SBE-β-CD lipid nanoparticles with cultured KB cells. Purified lipid 9 nanoparticles from the second population obtained by size exclusion chromatography were 10 incubated with plated living cells in a growth medium for up to 2 h. Though the yield of 11 nanoparticles was very low due to the loss of material during column purification, the interaction 12 of a few SN-38-SBE-β-CD-lipid nanoparticles with KB cells was observed by time-lapse confocal 13 microscopy (Fig. 6a ). The fluorescence signal of SN-38 was too low to be measured in cells. nanoparticles was similar to that of the SN-38-SBE-β-CD complexes in both cell types for all 20 experiments. Importantly, SBE-β-CD-lipid nanoparticles (no SN-38) did not induce cytotoxicity, 21 strongly suggesting that this range of cyclodextrin concentrations is safe for drug delivery and 22
will not lead to unspecific effects. In addition, HeLa cells were on average less sensitive to the 23 effect of SN-38 than KB cells. Altogether, we attribute the lack of toxicity to the low 24 29 concentration of SN-38-SBE-β-CD-lipid nanoparticles used in these experiments, a consequence 1 of the large dilution during size exclusion chromatography. In spite of its activity against tumor cells in vitro, the clinical use of SN-38 (and other hydrophobic 2 compounds) for chemotherapy remains limited due to its limited solubility and instability at 3 physiological pH. To solve these problems, a variety of liposomal formulations have been 4 developed [6] . In recent years, drug-in-cyclodextrin-in-liposomes have been designed to further 5 improve the delivery properties [33] . Complexation of SN-38 with SBE-β-CD greatly increases its 6 solubility [28]. In the present study, the development of SN-38-in-cyclodextrin-in-liposomes has 7 been explored. We have attempted to equip this system with folic acid as a ligand for targeted 8 delivery and with polyethylene glycol to manage highly stable, long-circulating lipid particles. 9
With the ultimate goal of developing liposomes that selectively deliver SN-38 to tumor cells, we 10 developed a formulation of folic acid-labelled liposomes. For more than two decades, folate 11 receptors have been intensively studied as tumor-specific drug delivery targets [37] [38] [39] [40] . Here, 12
we demonstrated selective uptake of folate-labelled HSPC-liposomes by cultured cells 13 expressing folate receptors (Fig. 2c) . In vivo, this would translate into an increased tumor 14 accumulation of liposomes compared to non-targeted liposomes. However, the degree of 15 increase is highly variable and in vivo studies would be required to evaluate the tumor targeting 16 potential of this liposome formulation to folate receptor-overexpressing tumors [40] . 17
As a first approach to solubilize and protect SN-38, we developed a formulation of SN-38-loaded-18 HSPC liposomes. The production of lipid-coated beads enabled the optimal storage of the SN-19 38-lipid formulation for months and presumably leads to a higher concentration of generated 20 liposomes and an enhanced drug-encapsulation efficiency thanks to the increased surface area 21 provided by the glass beads compared to ordinary methods [41, 42] . Preliminary liposome 22 characterization by fluorescence microscopy and dynamic light scattering demonstrated that 23 the presence of SN-38 did not interfere with the formation or stability of these lipid vesicles (Fig.  24 2a, b). This was an important verification considering that some lipophilic drugs are known to 25 interfere with bilayer formation and stability upon entrapment [23, 24] . The observed variability 1 on the fractions at which liposomes eluted during size exclusion chromatography can be 2 attributed to inherent differences between the purification columns (e.g. resine packing, 3 amount of resine), as they were handmade for each sample (Fig. 3a, b) . Successful entrapment 4 of some SN-38 molecules in HSPC-liposomes was demonstrated and a larger fraction of SN-38 5 was shown to interact if the sample was incubated prior to purification (Fig. 3b ). Since the buffer 6 used to generate the liposomes was acidic, all SN-38 molecules were in the closed lactone ring 7 conformation. Due to the high hydrophobicity of the lactone SN-38, the drug is expected to be 8 buried in the lipid bilayer [3] . In particular, the long 18-carbon acyl chains of HSPC could favor 9 the entrapment of SN-38 into the membrane. A different formulation of SN-38-loaded 10 liposomes, named LE-SN-38, has previously been created and SN-38 was found to localize in the 11 outer leaflet of the liposome bilayer, at the water interface [3] . In our study, the rapid release 12 of SN-38 from HSPC liposomes indicates a weak interaction (Fig. 3e) that large amounts of cyclodextrin could be lethal to cells, we first characterized the 26 32 solubilization of SN-38 at low SBE-β-CD to drug molar ratios, and found that a value of 1:8 1 offered a good comprise between effective solubilization of SN-38 and absolute cyclodextrin 2 concentration for further cytotoxicity assays (Fig. 4c) . 3
Though the concept of drug-in-cyclodextrin-in-liposomes as drug delivery system was first 4
proposed more than two decades ago [24], cyclodextrin-drug complexation competes with 5 liposomal membrane assembly, tempering the potential benefit of complexation in prolonging 6 hydrophobic drug retention [44] . Earlier studies on the effect of different cyclodextrins on the 7 integrity of liposomes reported that vesicles can collapse due to cyclodextrin-induced extraction 8 of lipids, causing the formation of water soluble lipid-cyclodextrin complexes. Moreover, this 9 effect depends on the cyclodextrin type and the length of the lipid fatty acid chain [43, 45, 46] . 10
Herein, we showed that SN-38-in-SBE-β-CD-in-liposomes fail to self-assemble at 1:8 drug to 11 cyclodextrin molar ratio ( Fig. 5 ). Instead, size exclusion chromatography and fluorescence 12 confocal microscopy revealed that SN-38 is trapped in lipid nanoparticles, likely arising from a 13 cyclodextrin-induced lipid extraction mechanism. Under certain conditions, cyclodextrin 14 molecules and their ligands can form non-inclusion aggregates with a size ranging from 20 to 15 100 nm in diameter [47] . We hypothesized that the observed nano-aggregates comprise SN-38-16 SBE-β-CD and lipid-SBE-β-CD inclusion complexes. Their nearly identical elution profiles suggest 17 that both types of particles have similar sizes (Fig. 5c ). It is known that the aggregation 18 propensity and the size of the aggregates increase with increasing cyclodextrin concentration 19
[47]. The optical microscopy experiments performed here should be complemented with 20 transmission electron microscopy measurements to determine the size, morphology and exact 21 molecular structure of these nanoparticles. 
